AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11520010 — intervention group
Group type: EXPERIMENTAL
Intervention: VR exposure flights
Number of subjects: 30
Study 11520010 — intervention group
Group type: COMPARATOR
Intervention: Both groups (VR and relaxation)
Number of subjects: 30
Study 11520010 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 30
Study 9480468 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic regimen (gentamicin, clindamycin)
Number of subjects: 104
Study 9480468 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative antibiotic treatment (intraoperatively)
Number of subjects: 104
Study 9480468 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with prolonged antibiotic administration
Number of subjects: 104
Study 9480468 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic or curative antibiotics)
Number of subjects: 104
Study 8098389 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (300 units/kg to a maximum of 30,000 units) for 14 days
Number of subjects: 208
Study 8098389 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin for 9 days (starting 6 days before surgery)
Number of subjects: 208
Study 8098389 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 208
Study 2433406 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin, bleomycin, and methotrexate with oral calcium leucovorin (PBM)
Number of subjects: 0
Study 2433406 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with PBM
Number of subjects: 0
Study 2433406 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy
Number of subjects: 0
Study 31945197 — intervention group
Group type: COMPARATOR
Intervention: URO-902 5000 µg
Number of subjects: 34
Study 31945197 — intervention group
Group type: COMPARATOR
Intervention: URO-902 10,000 µg
Number of subjects: 34
Study 31945197 — intervention group
Group type: COMPARATOR
Intervention: URO-902 16,000 µg
Number of subjects: 34
Study 31945197 — intervention group
Group type: COMPARATOR
Intervention: URO-902 24,000 µg
Number of subjects: 34
Study 31945197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 29316832 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Enabling and Support (IES)
Number of subjects: 0
Study 29316832 — intervention group
Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 0
Study 27028380 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiltse approach
Number of subjects: 69
Study 27028380 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach
Number of subjects: 69
Study 27028380 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 69
Study 24650323 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 220
Study 24650323 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol chewing gum
Number of subjects: 220
Study 24650323 — intervention group
Group type: COMPARATOR
Intervention: Gum base
Number of subjects: 220
Study 24650323 — intervention group
Group type: COMPARATOR
Intervention: No gum
Number of subjects: 220
Study 23695482 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy (within 4 days)
Number of subjects: 909
Study 23695482 — intervention group
Group type: COMPARATOR
Intervention: Late tracheostomy (after 10 days if still indicated)
Number of subjects: 909
Study 20610442 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with infliximab
Number of subjects: 13959
Study 20610442 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with methotrexate
Number of subjects: 13959
Study 20610442 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of joints
Number of subjects: 13959
Study 18717606 — intervention group
Group type: EXPERIMENTAL
Intervention: BenzaClin
Number of subjects: 40
Study 18717606 — intervention group
Group type: EXPERIMENTAL
Intervention: Duac
Number of subjects: 40
Study 18717606 — intervention group
Group type: COMPARATOR
Intervention: 0.2% sodium laurilsulfate (SLS)
Number of subjects: 40
Study 18717606 — intervention group
Group type: COMPARATOR
Intervention: White petrolatum
Number of subjects: 40
Study 16390893 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg/day (with titration options to 5 mg/day or 20 mg/day)
Number of subjects: 280
Study 16390893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 14662212 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid-containing multivitamin supplementation
Number of subjects: 2471
Study 14662212 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented group
Number of subjects: 2471
Study 14662212 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data of supplemented group
Number of subjects: 2471
Study 14662212 — intervention group
Group type: COMPARATOR
Intervention: Combined data of unsupplemented group
Number of subjects: 2471
Study 11287025 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride maleate (0.2 mg daily for 2 months)
Number of subjects: 60
Study 11287025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.2 mg daily for 2 months)
Number of subjects: 60
Study 11287025 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride maleate
Number of subjects: 60
Study 11287025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9256832 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic penicillin after 5 years of age
Number of subjects: 226
Study 9256832 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 5 years of age
Number of subjects: 226
Study 8255017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide
Number of subjects: 8
Study 8255017 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 8
Study 2886200 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol hydrochloride 0.5% with 2% pilocarpine (17 patients)
Number of subjects: 54
Study 2886200 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol hydrochloride 1% with 2% pilocarpine (19 patients)
Number of subjects: 54
Study 2886200 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% with 2% pilocarpine (18 patients)
Number of subjects: 54
Study 31145549 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin D levels <10 ng/mL
Number of subjects: 496
Study 31145549 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin D levels ≥10 ng/mL
Number of subjects: 496
Study 31145549 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin D level ≥10 ng/mL
Number of subjects: 496
Study 28081633 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-oriented treatment (10 days, 30 minutes each day)
Number of subjects: 66
Study 28081633 — intervention group
Group type: COMPARATOR
Intervention: Structural-oriented treatment (conventional therapy, 10 days, 30 minutes each day)
Number of subjects: 66
Study 25651367 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Number of subjects: 505
Study 25651367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study 24273976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianxinfu adsorbable biomembrane + Ligustrazine Injection (Group C)
Number of subjects: 120
Study 24273976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianxinfu adsorbable biomembrane + Danhong Injection (Group D)
Number of subjects: 120
Study 24273976 — intervention group
Group type: COMPARATOR
Intervention: Dikang adsorbable biomembrane (Group A)
Number of subjects: 120
Study 24273976 — intervention group
Group type: COMPARATOR
Intervention: Tianxinfu adsorbable biomembrane (Group B)
Number of subjects: 120
Study 24273976 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C, D)
Number of subjects: 120
Study 21804283 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal intervention (T2DM-T group)
Number of subjects: 190
Study 19695955 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG-F
Number of subjects: 201
Study 19695955 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 201
Study 16877662 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antenatal care plus the intervention
Number of subjects: 99
Study 16877662 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care only
Number of subjects: 99
Study 12634994 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum cream (1.5% hyperforin)
Number of subjects: 21
Study 12634994 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 21
Study 11226005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab at escalated doses (initial dose of 375 mg/m2, maximum dose of 2,250 mg/m2)
Number of subjects: 0
Study 11226005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 8776812 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide + flutamide
Number of subjects: 150
Study 8776812 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 150
Study 1290977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 17
Study 1290977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 17
Study 1290977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid
Number of subjects: 17
Study 6374055 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin 90 mg/m2 every three weeks (20 patients)
Number of subjects: 42
Study 6374055 — intervention group
Group type: COMPARATOR
Intervention: Observation (22 patients)
Number of subjects: 42
Study 6374055 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin
Number of subjects: 42
Study 31647277 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy
Number of subjects: 129
Study 31647277 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-enhanced nondirective supportive therapy
Number of subjects: 129
Study 29546335 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptome analysis of the alimentary tract (AT) of Ectropis oblique
Number of subjects: 0
Study 29546335 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative real‐time polymerase chain reaction (qRT-PCR) for 21 selected genes
Number of subjects: 0
Study 26370923 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/d
Number of subjects: 37
Study 26370923 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/d plus Metformin 2000 mg/d
Number of subjects: 37
Study 24423186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferrous sucrose (200 mg/24 hours for two consecutive days)
Number of subjects: 72
Study 24423186 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 72
Study 23078574 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (5 cups of 6-ounce cups per day)
Number of subjects: 42
Study 23078574 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (5 cups of 6-ounce cups per day)
Number of subjects: 42
Study 23078574 — intervention group
Group type: COMPARATOR
Intervention: Water (control group, 5 cups of 6-ounce cups per day)
Number of subjects: 42
Study 21062875 — intervention group
Group type: COMPARATOR
Intervention: Bilateral auscultation of the chest
Number of subjects: 160
Study 21062875 — intervention group
Group type: COMPARATOR
Intervention: Observation and palpation of symmetrical chest movements
Number of subjects: 160
Study 21062875 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of the position of the tube by the insertion depth
Number of subjects: 160
Study 21062875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three methods (auscultation, observation, tube depth)
Number of subjects: 160
Study 17617279 — intervention group
Group type: COMPARATOR
Intervention: Pramlintide 30 to 60 microg QID
Number of subjects: 243
Study 17617279 — intervention group
Group type: COMPARATOR
Intervention: Pramlintide 60 microg TID
Number of subjects: 243
Study 17617279 — intervention group
Group type: COMPARATOR
Intervention: Pramlintide 60 microg QID
Number of subjects: 243
Study 17617279 — intervention group
Group type: COMPARATOR
Intervention: Pramlintide 120 microg BID
Number of subjects: 243
Study 17617279 — intervention group
Group type: COMPARATOR
Intervention: Pramlintide 150 microg TID
Number of subjects: 243
Study 15893085 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 85
Study 15893085 — intervention group
Group type: COMPARATOR
Intervention: Standardized Brief Advice (BA)
Number of subjects: 85
Study 11916764 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg DHA + 70 mg EPA
Number of subjects: 120
Study 11916764 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg DHA + 140 mg EPA
Number of subjects: 120
Study 11916764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9475137 — intervention group
Group type: EXPERIMENTAL
Intervention: Home program plus supervised rehabilitation (Group S)
Number of subjects: 31
Study 9475137 — intervention group
Group type: COMPARATOR
Intervention: Home program (Group H)
Number of subjects: 31
Study 9185039 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with subconjunctival retention of 0.5 mL pure C3F8 gas (Group B)
Number of subjects: 32
Study 9185039 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy alone (Group A)
Number of subjects: 32
Study 9185039 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 32
Study 1981075 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg given once a day for 4 days)
Number of subjects: 0
Study 1981075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1981075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 0
Study 1981075 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0
Study 7019300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment consisting of preliminary chemotherapy (AVM or CMF), radiotherapy, and follow-up adjuvant chemotherapy.
Number of subjects: 74
Study 30694576 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Number of subjects: 236
Study 30694576 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg
Number of subjects: 236
Study 30694576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 29032921 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimel eye drops (Manuka honey) used twice a day for two weeks
Number of subjects: 24
Study 29032921 — intervention group
Group type: COMPARATOR
Intervention: Conventional lubricant (Systane Ultra) therapy used for two weeks
Number of subjects: 24
Study 25431280 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity (HI)
Number of subjects: 12
Study 25431280 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Intensity with Blood Flow Restriction (LI-BFR)
Number of subjects: 12
Study 25431280 — intervention group
Group type: COMPARATOR
Intervention: Low Intensity (LI)
Number of subjects: 12
Study 24658707 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4
Number of subjects: 0
Study 24658707 — intervention group
Group type: COMPARATOR
Intervention: Human albumin
Number of subjects: 0
Study 22533900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling of moderate-to-vigorous physical activity intervention
Number of subjects: 278
Study 22533900 — intervention group
Group type: COMPARATOR
Intervention: Print/website materials-only condition
Number of subjects: 278
Study 20978545 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery-based treatment
Number of subjects: 133
Study 20978545 — intervention group
Group type: COMPARATOR
Intervention: Radiation-based treatment
Number of subjects: 133
Study 17079058 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum adjuvanted eleven‐valent pneumococcal conjugate vaccine (11PncTD)
Number of subjects: 0
Study 17079058 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only DTwP/PRP‐T
Number of subjects: 0
Study 16123103 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (10 microm)
Number of subjects: 15
Study 16123103 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (20 microm)
Number of subjects: 15
Study 16123103 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P + 10 mm L-NAME
Number of subjects: 15
Study 16123103 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P + 500 microm pyrilamine
Number of subjects: 15
Study 16123103 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P + 10 mm L-NAME + 500 microm pyrilamine
Number of subjects: 15
Study 16123103 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of Substance P
Number of subjects: 15
Study 16123103 — intervention group
Group type: COMPARATOR
Intervention: Control site (Substance P only)
Number of subjects: 15
Study 12153837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous yohimbine
Number of subjects: 30
Study 12153837 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 30
Study 10533327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal Misoprostol® 200 ug
Number of subjects: 145
Study 10533327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal Misoprostol® 400 ug
Number of subjects: 145
Study 10533327 — intervention group
Group type: COMPARATOR
Intervention: Combined intramuscular oxytocin and ergometrine (O‐E)
Number of subjects: 145
Study 10533327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal Misoprostol® (200 ug and 400 ug)
Number of subjects: 145
Study 10533327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal Misoprostol®
Number of subjects: 145
Study 8537692 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 units of hyaluronidase per one-half liter
Number of subjects: 25
Study 8537692 — intervention group
Group type: COMPARATOR
Intervention: 150 units of hyaluronidase per one-half liter
Number of subjects: 25
Study 2261719 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning barium meal examinations
Number of subjects: 60
Study 2261719 — intervention group
Group type: COMPARATOR
Intervention: Afternoon barium meal examinations
Number of subjects: 60
Study 542823 — intervention group
Group type: EXPERIMENTAL
Intervention: Björk-Shiley (B-S) valves
Number of subjects: 79
Study 542823 — intervention group
Group type: COMPARATOR
Intervention: Lillehei-Kaster (L-K) valves
Number of subjects: 79
Study 31834252 — intervention group
Group type: COMPARATOR
Intervention: Statins (10 mg of rosuvastatin)
Number of subjects: 83
Study 31834252 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Exercise Training (PLET)
Number of subjects: 83
Study 31834252 — intervention group
Group type: COMPARATOR
Intervention: Statins + Exercise Training (STAET)
Number of subjects: 83
Study 30589927 — intervention group
Group type: EXPERIMENTAL
Intervention: Creation of subperiosteal tunnels prior to lateral osteotomies
Number of subjects: 34
Study 30589927 — intervention group
Group type: COMPARATOR
Intervention: Control side (without creation of subperiosteal tunnels)
Number of subjects: 34
Study 28120631 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent dyadic intervention including physical exercise and support
Number of subjects: 111
Study 28120631 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (monthly written information bulletins and monthly phone calls)
Number of subjects: 111
Study 26433799 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (8 sessions, twice a week for 4 weeks)
Number of subjects: 50
Study 26433799 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg three times a day for 10 days)
Number of subjects: 50
Study 23884046 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week educational intervention involving weekly 60-minute sessions (Group A)
Number of subjects: 13
Study 23884046 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 13
Study 21911858 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Play (FP)
Number of subjects: 20
Study 21911858 — intervention group
Group type: COMPARATOR
Intervention: 1 touch (1T)
Number of subjects: 20
Study 21911858 — intervention group
Group type: COMPARATOR
Intervention: 2 touches (2T)
Number of subjects: 20
Study 20011748 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing Index (BI2) after Gingival Bleeding Index (GBI1)
Number of subjects: 34
Study 20011748 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing Index (BI1) before Gingival Bleeding Index (GBI2)
Number of subjects: 34
Study 20011748 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival Bleeding Index (GBI1) and Brushing Index (BI2)
Number of subjects: 34
Study 20011748 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing Index (BI1) and Gingival Bleeding Index (GBI2)
Number of subjects: 34
Study 17395677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg daily
Number of subjects: 2755
Study 17395677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2755
Study 15132341 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP clinic evaluation (full evaluation)
Number of subjects: 235
Study 15132341 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP clinic evaluation (some components)
Number of subjects: 235
Study 15132341 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP clinic evaluation (only primary care appointment)
Number of subjects: 235
Study 15132341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 235
Study 15132341 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behavior counseling
Number of subjects: 235
Study 15132341 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care visits after HELP clinic contact
Number of subjects: 235
Study 11133617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi‐Contour Cuff
Number of subjects: 50
Study 11133617 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile Soft‐Seal Cuff
Number of subjects: 50
Study 11133617 — intervention group
Group type: COMPARATOR
Intervention: All groups (Hi‐Contour, Sheridan, Rush, Reinforce, Profile Soft‐Seal Cuff)
Number of subjects: 50
Study 9754454 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 8